- Published at
- by gurufocus.com
neutral
neutral
Kalaris Reports First Quarter 2025 Financial Results and Provides Business Highlights
Actively enrolling nAMD patients in a Phase 1 trial of TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and incre